Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
IOL CHEMICALS & PHARM. ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IOL CHEMICALS & PHARM. Mar-23 |
ACTAVIS Dec-18 |
IOL CHEMICALS & PHARM./ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 537 | 16,136 | - | |
Low | Rs | 272 | 10,824 | - | |
Sales per share (Unadj.) | Rs | 377.6 | 3,958.1 | - | |
Earnings per share (Unadj.) | Rs | 23.7 | -1,274.9 | - | |
Cash flow per share (Unadj.) | Rs | 31.6 | 417.1 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 256.8 | 16,325.5 | - | |
Shares outstanding (eoy) | m | 58.71 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.1 | 3.4 | 31.4% | |
Avg P/E ratio | x | 17.1 | -10.6 | -161.4% | |
P/CF ratio (eoy) | x | 12.8 | 32.3 | 39.6% | |
Price / Book Value ratio | x | 1.6 | 0.8 | 190.7% | |
Dividend payout | % | 16.9 | 0 | - | |
Avg Mkt Cap | Rs m | 23,743 | 4,483,446 | 0.5% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 1,682 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,898.1 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,091.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 22,171 | 1,316,478 | 1.7% | |
Other income | Rs m | 256 | 25,175 | 1.0% | |
Total revenues | Rs m | 22,427 | 1,341,653 | 1.7% | |
Gross profit | Rs m | 2,257 | 34,498 | 6.5% | |
Depreciation | Rs m | 462 | 562,766 | 0.1% | |
Interest | Rs m | 165 | 75,968 | 0.2% | |
Profit before tax | Rs m | 1,887 | -579,060 | -0.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,684 | 0.0% | |
Tax | Rs m | 495 | -7,338 | -6.7% | |
Profit after tax | Rs m | 1,391 | -424,038 | -0.3% | |
Gross profit margin | % | 10.2 | 2.6 | 388.4% | |
Effective tax rate | % | 26.2 | 1.3 | 2,070.9% | |
Net profit margin | % | 6.3 | -32.2 | -19.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,667 | 539,950 | 1.8% | |
Current liabilities | Rs m | 5,025 | 477,658 | 1.1% | |
Net working cap to sales | % | 20.9 | 4.7 | 442.4% | |
Current ratio | x | 1.9 | 1.1 | 170.2% | |
Inventory Days | Days | 43 | 20 | 221.0% | |
Debtors Days | Days | 8 | 66 | 12.5% | |
Net fixed assets | Rs m | 11,017 | 149,018 | 7.4% | |
Share capital | Rs m | 587 | 0 | - | |
Net worth | Rs m | 15,077 | 5,429,856 | 0.3% | |
Long term debt | Rs m | 0 | 1,912,049 | 0.0% | |
Total assets | Rs m | 20,684 | 8,488,101 | 0.2% | |
Interest coverage | x | 12.5 | -6.6 | -188.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 1.1 | 0.2 | 691.1% | |
Return on assets | % | 7.5 | -4.1 | -183.5% | |
Return on equity | % | 9.2 | -7.8 | -118.2% | |
Return on capital | % | 13.6 | -4.8 | -281.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,223 | 470,328 | 0.3% | |
From Investments | Rs m | -1,200 | 258,384 | -0.5% | |
From Financial Activity | Rs m | -41 | -807,224 | 0.0% | |
Net Cashflow | Rs m | -18 | -78,120 | 0.0% |
Compare IOL CHEMICALS & PHARM. With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare IOL CHEMICALS & PHARM. With: GANGA PHARMACEUTICALS BH.IMMUN&BIO WOCKHARDT CONCORD DRUGS JAGSON PHAR
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended on firm footing.